Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: Association with other clinical and laboratory parameters

Ádám Kemény-Beke, R. Gesztelyi, Nóra Bodnár, Judit Zsuga, G. Kerekes, M. Zsuga, Bernadett Biri, S. Kéki, Péter Szodoray, A. Berta, Z. Szekanecz, S. Szántó

Research output: Article

19 Citations (Scopus)

Abstract

Objective: Asymmetric dimethylarginine (ADMA) has been associated with atherosclerosis, vascular diseases and, recently, also with arthritis including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Methods: Serum ADMA, arginine and symmetric dimethylarginine (SDMA) levels were assessed by liquid chromatography in 61 AS and 26 osteoarthritis (OA) patients with no known cardiovascular disease. Results: Serum ADMA levels were significantly increased in AS compared to OA patients (0.95. ± 0.17. μM versus 0.70. ± 0.25. μM; p<0.001). There were no differences in serum arginine and SDMA levels. Serum ADMA levels also positively correlated with age (R= 0.258; p= 0.043), body mass index (R= 0.368; p= 0.003), erythrocyte sedimentation rate (R= 0.329; p= 0.009) and ADMA levels negative correlated with chest expansion (R= -0.251; p= 0.04). No correlations were found between ADMA levels and disease duration, pain intensity, BASDAI, BASFI, BASMI, quality of life, CRP, HLA-B27 positivity, endothelial dysfunction or carotid atherosclerosis. Conclusion: ADMA may serve as a marker of systemic inflammation and may reflect functional immobility in AS. Further studies are needed to assess the possible role of ADMA in AS and AS-related vascular disease.

Original languageEnglish
Pages (from-to)184-187
Number of pages4
JournalJoint Bone Spine
Volume78
Issue number2
DOIs
Publication statusPublished - márc. 2011

Fingerprint

Ankylosing Spondylitis
Serum
Vascular Diseases
Osteoarthritis
Arginine
HLA-B27 Antigen
Carotid Artery Diseases
N,N-dimethylarginine
Blood Sedimentation
Liquid Chromatography
Arthritis
Rheumatoid Arthritis
Atherosclerosis
Body Mass Index
Cardiovascular Diseases
Thorax
Quality of Life
Inflammation
Pain

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{536e6b122a424bef8ca7a13d82f116df,
title = "Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: Association with other clinical and laboratory parameters",
abstract = "Objective: Asymmetric dimethylarginine (ADMA) has been associated with atherosclerosis, vascular diseases and, recently, also with arthritis including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Methods: Serum ADMA, arginine and symmetric dimethylarginine (SDMA) levels were assessed by liquid chromatography in 61 AS and 26 osteoarthritis (OA) patients with no known cardiovascular disease. Results: Serum ADMA levels were significantly increased in AS compared to OA patients (0.95. ± 0.17. μM versus 0.70. ± 0.25. μM; p<0.001). There were no differences in serum arginine and SDMA levels. Serum ADMA levels also positively correlated with age (R= 0.258; p= 0.043), body mass index (R= 0.368; p= 0.003), erythrocyte sedimentation rate (R= 0.329; p= 0.009) and ADMA levels negative correlated with chest expansion (R= -0.251; p= 0.04). No correlations were found between ADMA levels and disease duration, pain intensity, BASDAI, BASFI, BASMI, quality of life, CRP, HLA-B27 positivity, endothelial dysfunction or carotid atherosclerosis. Conclusion: ADMA may serve as a marker of systemic inflammation and may reflect functional immobility in AS. Further studies are needed to assess the possible role of ADMA in AS and AS-related vascular disease.",
keywords = "ADMA, Ankylosing spondylitis, Atherosclerosis, Cardiovascular disease",
author = "{\'A}d{\'a}m Kem{\'e}ny-Beke and R. Gesztelyi and N{\'o}ra Bodn{\'a}r and Judit Zsuga and G. Kerekes and M. Zsuga and Bernadett Biri and S. K{\'e}ki and P{\'e}ter Szodoray and A. Berta and Z. Szekanecz and S. Sz{\'a}nt{\'o}",
year = "2011",
month = "3",
doi = "10.1016/j.jbspin.2010.05.009",
language = "English",
volume = "78",
pages = "184--187",
journal = "Revue du Rhumatisme (English Edition)",
issn = "1169-8446",
publisher = "Elsevier Masson",
number = "2",

}

TY - JOUR

T1 - Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis

T2 - Association with other clinical and laboratory parameters

AU - Kemény-Beke, Ádám

AU - Gesztelyi, R.

AU - Bodnár, Nóra

AU - Zsuga, Judit

AU - Kerekes, G.

AU - Zsuga, M.

AU - Biri, Bernadett

AU - Kéki, S.

AU - Szodoray, Péter

AU - Berta, A.

AU - Szekanecz, Z.

AU - Szántó, S.

PY - 2011/3

Y1 - 2011/3

N2 - Objective: Asymmetric dimethylarginine (ADMA) has been associated with atherosclerosis, vascular diseases and, recently, also with arthritis including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Methods: Serum ADMA, arginine and symmetric dimethylarginine (SDMA) levels were assessed by liquid chromatography in 61 AS and 26 osteoarthritis (OA) patients with no known cardiovascular disease. Results: Serum ADMA levels were significantly increased in AS compared to OA patients (0.95. ± 0.17. μM versus 0.70. ± 0.25. μM; p<0.001). There were no differences in serum arginine and SDMA levels. Serum ADMA levels also positively correlated with age (R= 0.258; p= 0.043), body mass index (R= 0.368; p= 0.003), erythrocyte sedimentation rate (R= 0.329; p= 0.009) and ADMA levels negative correlated with chest expansion (R= -0.251; p= 0.04). No correlations were found between ADMA levels and disease duration, pain intensity, BASDAI, BASFI, BASMI, quality of life, CRP, HLA-B27 positivity, endothelial dysfunction or carotid atherosclerosis. Conclusion: ADMA may serve as a marker of systemic inflammation and may reflect functional immobility in AS. Further studies are needed to assess the possible role of ADMA in AS and AS-related vascular disease.

AB - Objective: Asymmetric dimethylarginine (ADMA) has been associated with atherosclerosis, vascular diseases and, recently, also with arthritis including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Methods: Serum ADMA, arginine and symmetric dimethylarginine (SDMA) levels were assessed by liquid chromatography in 61 AS and 26 osteoarthritis (OA) patients with no known cardiovascular disease. Results: Serum ADMA levels were significantly increased in AS compared to OA patients (0.95. ± 0.17. μM versus 0.70. ± 0.25. μM; p<0.001). There were no differences in serum arginine and SDMA levels. Serum ADMA levels also positively correlated with age (R= 0.258; p= 0.043), body mass index (R= 0.368; p= 0.003), erythrocyte sedimentation rate (R= 0.329; p= 0.009) and ADMA levels negative correlated with chest expansion (R= -0.251; p= 0.04). No correlations were found between ADMA levels and disease duration, pain intensity, BASDAI, BASFI, BASMI, quality of life, CRP, HLA-B27 positivity, endothelial dysfunction or carotid atherosclerosis. Conclusion: ADMA may serve as a marker of systemic inflammation and may reflect functional immobility in AS. Further studies are needed to assess the possible role of ADMA in AS and AS-related vascular disease.

KW - ADMA

KW - Ankylosing spondylitis

KW - Atherosclerosis

KW - Cardiovascular disease

UR - http://www.scopus.com/inward/record.url?scp=79952242688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952242688&partnerID=8YFLogxK

U2 - 10.1016/j.jbspin.2010.05.009

DO - 10.1016/j.jbspin.2010.05.009

M3 - Article

C2 - 20620092

AN - SCOPUS:79952242688

VL - 78

SP - 184

EP - 187

JO - Revue du Rhumatisme (English Edition)

JF - Revue du Rhumatisme (English Edition)

SN - 1169-8446

IS - 2

ER -